## HOUSE SUMMARY OF SENATE AMENDMENTS

## HB 319 2015 Regular Session Simon

DRUGS/PRESCRIPTION: Provides relative to the dispensing of interchangeable biological products

## **Synopsis of Senate Amendments**

- 1. Amend the definition of an "equivalent product" and remove the definition of "interchangeable".
- 2. Remove the requirement for an interchangeable biological products list to be maintained on the Louisiana Board of Pharmacy's web page.
- 3. Delete the enumerated authorized means of communication to allow the communication to be done by any means.
- 4. Clarify that no communication is required if there is no interchangeable or therapeutically equivalent biological product approved by FDA.
- 5. Provide that nothing in <u>proposed law</u> creates a cause of action against the prescriber and the dispensing pharmacist or his designee as a result of the required communication.
- 6. Provide that no communication will be required if the prescriber indicates dispense as written.
- 7. Delete provisions relative to licensure penalties.
- 8. Make technical changes.

## Digest of Bill as Finally Passed by Senate

Proposed law defines "biological product" and "equivalent drug product".

<u>Proposed law</u> requires the dispensing pharmacist or his designee, no later than five business days following the dispensing of a biological product, to communicate to the prescriber the specific product provided to the patient, including the name of the product and the manufacturer.

<u>Proposed law</u> authorizes the required communication to be done by any means.

<u>Proposed law provides no communication is required if any of the following conditions exist:</u>

- (1) There is no interchangeable or therapeutical equivalent biological product approved by the United States Food and Drug Administration (FDA) for the product prescribed.
- (2) The prescription is a refill not changed from the product dispensed on the prior filling of the prescription.
- (3) The prescriber indicates dispense as written.

Nothing in <u>proposed law</u> creates a cause of action against the prescriber and the dispensing pharmacist or his designee for a communication as required pursuant to proposed law.

(Amends R.S. 37:1164(16); adds R.S. 37:1164(58) and 1226.1)